Human AFG3L2/SCA28/SPAX5 ORF/cDNA clone-Lentivirus particle (NM_006796)

Cat. No.: vGMLP001596

Pre-made Human AFG3L2/SCA28/SPAX5 Lentiviral expression plasmid for AFG3L2 lentivirus packaging, AFG3L2 lentivirus production, overexpression stable cell line development, cell transient transfection and gene delivery targeting T/B/NK cells, macrophages, cardiomyocytes, hepatocytes, and neurons.

The GM Vector Core (GMVC) specializes in custom lentivirus development and offers a range of lentivirus manufacturing solutions, leveraging state-of-the-art processes. Learn more about our services.

Target products collection

Go to AFG3L2/SCA28 products collection>>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdf MSDS
pdf Datasheet

Product information

Catalog No. Product Name lentivirus Grade lentivirus quantity
vGMLP001596 Human AFG3L2 Lentivirus particle Pilot Grade 1.0E+8TU
5.0E+8TU
1.0E+9TU
Research Grade 1.0E+8TU
5.0E+8TU
1.0E+9TU
GMP-like Grade inquiry
GMP Grade inquiry


Product Description

Catalog ID vGMLP001596
Gene Name AFG3L2
Accession Number NM_006796
Gene ID 10939
Species Human
Product Type Lentivirus particle (overexpression)
Insert Length 2394 bp
Gene Alias SCA28,SPAX5
Fluorescent Reporter ZsGreen
Mammalian Cell Selection Puromyocin
Fusion Tag 3xflag (C-Terminal)
Promoter CMV
Resistance Amplicin
ORF Nucleotide Sequence ATGGCGCACCGCTGTTTGCGGCTGTGGGGCCGGGGCGGCTGCTGGCCCCGCGGCCTACAGCAGCTCCTCGTGCCTGGCGGCGTGGGCCCGGGCGAGCAGCCCTGCCTCCGGACGCTTTACCGATTTGTTACAACTCAAGCAAGGGCCAGCAGAAATTCTCTTTTGACAGATATAATTGCTGCTTATCAAAGATTCTGTTCTCGACCCCCAAAAGGATTTGAAAAATACTTTCCTAATGGAAAAAATGGAAAAAAAGCTAGTGAACCTAAAGAAGTTATGGGAGAGAAAAAAGAATCAAAGCCAGCTGCTACCACACGCTCTTCTGGAGGAGGAGGTGGTGGCGGTGGAAAACGAGGTGGCAAGAAAGATGATTCTCACTGGTGGTCCAGGTTTCAGAAGGGTGACATTCCATGGGACGACAAGGATTTCAGGATGTTCTTCCTCTGGACTGCTCTGTTCTGGGGTGGAGTCATGTTTTACTTGCTGCTCAAGAGATCCGGGAGAGAAATCACTTGGAAGGACTTTGTCAATAACTATCTTTCAAAAGGAGTAGTAGACAGATTGGAAGTCGTCAACAAGCGTTTTGTTCGAGTGACCTTTACACCAGGAAAAACTCCTGTTGATGGGCAATACGTTTGGTTTAATATTGGCAGTGTGGACACCTTTGAACGGAATCTGGAAACTTTACAGCAGGAATTGGGCATAGAAGGAGAAAATCGGGTGCCTGTTGTCTACATTGCTGAAAGTGATGGCTCTTTTCTGCTGAGCATGCTGCCTACGGTGCTCATCATCGCCTTCTTGCTCTACACCATCAGAAGAGGGCCTGCTGGCATTGGCCGGACAGGCCGAGGGATGGGCGGACTCTTCAGTGTCGGAGAAACCACTGCCAAGGTCTTAAAGGATGAAATTGATGTGAAGTTCAAAGATGTGGCTGGCTGTGAGGAGGCCAAGCTAGAGATCATGGAATTTGTGAATTTCTTGAAAAACCCAAAGCAGTATCAAGACCTAGGAGCAAAAATCCCAAAGGGTGCCATTCTCACTGGTCCTCCAGGCACTGGGAAGACGCTGCTAGCTAAGGCCACAGCCGGAGAAGCCAATGTCCCCTTCATCACCGTTAGTGGATCTGAGTTTTTGGAGATGTTCGTTGGTGTGGGCCCTGCTAGAGTCCGAGACTTATTTGCCCTTGCTCGGAAGAATGCCCCTTGCATCCTCTTCATCGATGAAATCGATGCGGTGGGAAGGAAGAGAGGAAGAGGCAACTTTGGAGGGCAGAGTGAGCAGGAGAACACACTCAACCAGCTGCTGGTGGAGATGGATGGTTTTAATACAACAACAAATGTCGTCATTTTGGCCGGCACCAATCGACCAGATATCCTGGACCCCGCGCTGCTTAGGCCGGGGCGTTTCGACAGGCAGATCTTTATTGGACCACCAGACATAAAAGGAAGAGCTTCTATTTTCAAAGTTCATCTCCGACCGCTAAAACTGGACAGTACCCTGGAGAAGGATAAATTGGCAAGAAAACTGGCATCTTTAACTCCAGGGTTTTCAGGTGCTGATGTTGCTAATGTCTGTAATGAAGCTGCGTTGATTGCTGCAAGGCATCTGTCAGATTCCATAAATCAGAAACACTTTGAACAGGCAATTGAACGAGTGATTGGTGGCTTAGAGAAGAAAACGCAGGTTCTGCAGCCTGAGGAGAAGAAGACTGTGGCATACCACGAAGCAGGCCATGCGGTTGCCGGCTGGTATCTGGAGCACGCAGACCCGCTTTTAAAGGTATCCATCATCCCACGTGGCAAAGGACTAGGTTATGCTCAGTATTTACCAAAAGAACAATACCTCTATACCAAAGAGCAGCTCTTGGATAGGATGTGTATGACTTTAGGTGGTCGAGTCTCTGAAGAAATCTTCTTTGGAAGAATTACAACTGGTGCTCAAGATGACTTGAGAAAAGTAACTCAGAGTGCATATGCCCAAATTGTTCAGTTTGGCATGAATGAAAAGGTTGGGCAAATCTCCTTTGACCTCCCACGTCAGGGGGACATGGTATTGGAGAAACCTTACAGTGAAGCCACTGCAAGATTGATAGATGATGAAGTACGAATACTTATTAATGATGCTTATAAAAGAACAGTAGCTCTTCTCACAGAAAAGAAAGCTGACGTGGAGAAGGTTGCTCTTCTGTTGTTAGAAAAAGAAGTATTAGATAAGAATGATATGGTTGAACTTTTGGGCCCCAGACCATTTGCGGAAAAATCTACCTATGAAGAATTTGTGGAAGGCACTGGCAGCTTGGATGAGGACACCTCACTTCCAGAAGGCCTTAAGGACTGGAACAAGGAGCGGGAAAAGGAGAAAGAGGAGCCCCCGGGTGAGAAAGTTGCCAACTAG
ORF Protein Sequence MAHRCLRLWGRGGCWPRGLQQLLVPGGVGPGEQPCLRTLYRFVTTQARASRNSLLTDIIAAYQRFCSRPPKGFEKYFPNGKNGKKASEPKEVMGEKKESKPAATTRSSGGGGGGGGKRGGKKDDSHWWSRFQKGDIPWDDKDFRMFFLWTALFWGGVMFYLLLKRSGREITWKDFVNNYLSKGVVDRLEVVNKRFVRVTFTPGKTPVDGQYVWFNIGSVDTFERNLETLQQELGIEGENRVPVVYIAESDGSFLLSMLPTVLIIAFLLYTIRRGPAGIGRTGRGMGGLFSVGETTAKVLKDEIDVKFKDVAGCEEAKLEIMEFVNFLKNPKQYQDLGAKIPKGAILTGPPGTGKTLLAKATAGEANVPFITVSGSEFLEMFVGVGPARVRDLFALARKNAPCILFIDEIDAVGRKRGRGNFGGQSEQENTLNQLLVEMDGFNTTTNVVILAGTNRPDILDPALLRPGRFDRQIFIGPPDIKGRASIFKVHLRPLKLDSTLEKDKLARKLASLTPGFSGADVANVCNEAALIAARHLSDSINQKHFEQAIERVIGGLEKKTQVLQPEEKKTVAYHEAGHAVAGWYLEHADPLLKVSIIPRGKGLGYAQYLPKEQYLYTKEQLLDRMCMTLGGRVSEEIFFGRITTGAQDDLRKVTQSAYAQIVQFGMNEKVGQISFDLPRQGDMVLEKPYSEATARLIDDEVRILINDAYKRTVALLTEKKADVEKVALLLLEKEVLDKNDMVELLGPRPFAEKSTYEEFVEGTGSLDEDTSLPEGLKDWNKEREKEKEEPPGEKVAN

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    Category Cat No. Products Name
    Target Antibody GM-Tg-g-IP0303-Ab Anti-AFG3L2 monoclonal antibody
    Target Antigen GM-Tg-g-IP0303-Ag AFG3L2 protein
    ORF Viral Vector pGMLP001596 Human AFG3L2 Lentivirus plasmid
    ORF Viral Vector vGMLP001596 Human AFG3L2 Lentivirus particle


    Target information

    Target ID GM-IP0303
    Target Name AFG3L2
    Gene ID 10939, 69597, 114673744, 307350, 101097676, 490560, 515757, 100058377
    Gene Symbol and Synonyms 2310036I02Rik,AFG3L2,Emv66,OPA12,par,SCA28,SPAX5
    Uniprot Accession Q9Y4W6
    Uniprot Entry Name AFG32_HUMAN
    Protein Sub-location Introcelluar Protein
    Category Not Available
    Disease Not Available
    Gene Ensembl ENSG00000141385
    Target Classification Not Available

    This gene encodes a protein localized in mitochondria and closely related to paraplegin. The paraplegin gene is responsible for an autosomal recessive form of hereditary spastic paraplegia. This gene is a candidate gene for other hereditary spastic paraplegias or neurodegenerative disorders. [provided by RefSeq, Jul 2008]



    About GMVC

    GDU

    GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.